Management of Hepatocellular Carcinoma

Clinics in Liver Disease

Volumn 11, Issue 2, 2007, Pages 305-321

  del Pozo, Ana Carolina ^a   López, Patricia ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIRUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN C; MITOXANTRONE;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM STAGING;

EID: 34250865213     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.04.007     Document Type: Review

References (73)

1. Cormier J.N., Thomas K.T., Chari R.S., et al. Management of hepatocellular carcinoma. J Gastrointest Surg 10 5 (2006) 761-780
2. Lopez P.M., Villanueva A., and Llovet J.M. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. [review]. Aliment Pharmacol Ther 23 11 (2006) 1535-1547
3. Forner A., Hessheimer A.J., Isabel Real M., et al. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 60 2 (2006) 89-98
4. Makuuchi M., and Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl 10 2 Suppl 1 (2004) S46-S52
5. Llovet J.M., Fuster J., and Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30 (1999) 1434-1440
6. Spangenberg H.C., Thimme R., and Blum H.E. Serum markers of hepatocellular carcinoma. Semin Liver Dis 26 4 (2006) 385-390
7. Llovet J.M., Bru C., and Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19 (1999) 329-338
8. Fazakas J., Mandli T., Ther G., et al. Evaluation of liver function for hepatic resection. Transplant Proc 38 3 (2006) 798-800
9. Emond J.C., Samstein B., and Renz J.F. A critical evaluation of hepatic resection in cirrhosis: optimizing patient selection and outcomes. World J Surg 29 2 (2005) 124-130
10. Bruix J., Castells A., Bosch J., et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111 4 (1996) 1018-1022
11. Chik B.H., Liu C.L., Fan S.T., et al. Tumor size and operative risks of extended right-sided hepatic resection for hepatocellular carcinoma: implication for preoperative portal vein embolization. [discussion: 69]. Arch Surg 142 1 (2007) 63-69
12. Farges O., Belghiti J., Kianmanesh R., et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 237 2 (2003) 208-217
13. Kianmanesh R., Regimbeau J.M., and Belghiti J. Selective approach to major hepatic resection for hepatocellular carcinoma in chronic liver disease. Surg Oncol Clin N Am 12 1 (2003) 51-63
14. Shah S.A., Cleary S.P., Wei A.C., et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 141 3 (2007) 330-339
15. Tralhão J.G., Dagher I., Lino T., et al. Treatment of tumor recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients. Eur J Surg Oncol (2006) [Epub ahead of print]
16. Figueras J., Jaurrieta E., Valls C., et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 25 (1997) 1485-1489
17. Bismuth H., Chiche L., Adam R., et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 218 (1993) 145-151
18. Iwatsuki S., Starzl T.E., Sheahan D.G., et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 214 (1991) 221-228
19. Ringe B., Pichlmayr R., Wittekind C., et al. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 15 (1991) 270-285
20. Moreno P., Jaurrieta E., Figueras J., et al. Orthotopic liver transplantation: treatment of choice in cirrhotic patients with hepatocellular carcinoma?. Transplant Proc 27 (1995) 2296-2298
21. Mazzaferro V., Rondinara G.F., Rossi G., et al. Milan multicenter experience in liver transplantation for hepatocellular carcinoma. Transplant Proc 26 (1994) 3557-3560
22. Roayaie S., Schwartz J., Sung M.W., et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 10 (2004) 534-540
23. Marsh J., and Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure?. Liver Transpl 9 (2003) 693-696
24. Onaca N., Davis G., Goldstein R., et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the international registry of hepatic tumors in liver transplantation. Liver Transpl 13 (2007) 391-399
25. Schwartz M. Liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 10 2 Suppl 1 (2004) S81-S85
26. Sauer P., Kraus T.W., Schemmer P., et al. Liver transplantation for hepatocellular carcinoma: is there evidence for expanding the selection criteria. Transplantation 80 (2005) S105-S108
27. Yao F., Bass N., Nikolai B., et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 8 (2002) 873-883
28. Durand F., and Belghiti J. Liver transplantation for hepatocellular carcinoma: should we push the limits?. Liver Transpl 9 (2003) 697-699
29. Ringe B. Can the prognosis of liver transplantation for hepatocellular carcinoma be predicted?. Hepatology 26 (1997) 507-550
30. Cillo U., Vitale A., Bassanello M., et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 239 (2004) 150-159
31. Gondolesi G., Roayaie S., Munoz L., et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 239 (2004) 142-149
32. Gondolesi G., Munoz L., Matsumoto C., et al. Hepatocellular carcinoma: a prime indication for living donor liver transplantation. J Gastrointest Surg 6 (2002) 102-107
33. Roayaie S., Frischer J.S., Emre S.H., et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235 (2002) 533-539
34. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33 (2001) 1394-1403
35. Ikai I., Itai Y., Okita K., et al. Report of the 15th follow-up survey of primary liver cancer. Hepatol Res 28 (2004) 21-29
36. Shiina S., Tagawa K., Niwa Y., et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR Am J Roentgenol 160 (1993) 1023-1028
37. Ebara M., Okabe S., Kita K., et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 43 3 (2005) 458-464
38. Choi D., Lim H.K., Rhim H., et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol 17 3 (2007) 684-692
39. Lencioni R., Della Pina C., and Bartolozzi C. Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma. Abdom Imaging 30 4 (2005) 401-408
40. Livraghi T., Goldberg S.N., Lazzaroni S., et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210 (1999) 655-661
41. Lencioni R., Allgaier H.P., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 228 (2003) 235-240
42. Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129 1 (2005) 122-130
43. Poon R.T., Ngan H., Lo C.M., et al. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 73 (2000) 109-114
44. Carr B.I. Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients. Hepatogastroenterology 49 (2002) 79-86
45. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
46. Chok K.S., Ng K.K., Poon R.T., et al. Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization. Arch Surg 141 (2006) 1231-1236
47. Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30 1 (2007) 6-25
48. Jaeger H.J., Mehring U.M., Castaneda F., et al. Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Cardiovasc Intervent Radiol 19 (1996) 388-396
49. Makuuchi M., Sukigara M., Mori T., et al. Bile duct necrosis: complication of transcatheter hepatic arterial embolization. Radiology 156 (1985) 331-334
50. Rand T., Loewe C., Schoder M., et al. Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. Cardiovasc Intervent Radiol 28 (2005) 313-318
51. Georgiades C.S., Hong K., D'Angelo M., et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 16 (2005) 1653-1659
52. Morante A., Romano M., Cuomo A., et al. Massive gastric ulceration after transarterial chemoembolization for hepatocellular carcinoma. Gastrointest Endosc 63 (2006) 718-720 110
53. Huo T.I., Wu J.C., Lee P.C., et al. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 24 (2004) 210-215
54. Llovet J.M., Real M.I., Montana X., et al. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation vs symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
55. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 2 (2003) 429-442
56. Gray B.N., Burton M.A., Kelleher D.K., et al. Selective internal radiation (SIR) therapy for treatment of liver metastases: measurement of response rate. J Surg Oncol 42 (1989) 192-196
57. Sangro B., Bilbao J.I., Boan J., et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66 3 (2006) 792-800
58. Carr B.I. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 10 2 Suppl 1 (2004) S107-S110
59. Zhu A.X. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?. Oncologist 11 7 (2006) 790-800
60. Huang M., and Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett 135 (1999) 97-105
61. Kato A., Miyazaki M., Ambiru S., et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 78 (2001) 110-115
62. Kuo M.T., Zhao J.Y., Teeter L.D., et al. Activation of multidrug resistance (P glycoprotein) MDR3/MDR1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell Growth Differ 3 (1992) 531-540
63. Farinati F. Tamoxifen treatment in hepatocellular carcinoma. Gastroenterology 111 1 (1996) 272-274
64. Castells A., Bruix J., Bru C., et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 109 3 (1995) 917-922
65. Chow P.K., Tai B.C., Tan C.K., et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 36 5 (2002) 1221-1226
66. Claviere C., Bronowicki J.P., Hudziak H., et al. [Role of sex steroids and their receptors in the pathophysiology of hepatocellular carcinoma]. Gastroenterol Clin Biol 22 (1998) 73-86 [in French]
67. Francavilla A., Polimeno L., DiLeo A., et al. The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology 9 (1989) 614-620
68. Jiang S.Y., Shyu R.Y., Yeh M.Y., et al. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol 23 (1995) 712-719
69. Farinati F., Salvagnini M., de Maria N., et al. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 11 (1990) 297-301
70. Yeo W., Mok T.S., Zee B., et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97 (2005) 1532-1538
71. Hwang L.H. Gene therapy strategies for hepatocellular carcinoma. J Biomed Sci 13 4 (2006) 453-468
72. Hernandez-Alcoceba R., Sangro B., and Prieto J. Gene therapy of liver cancer. Ann Hepatol 6 1 (2007) 5-14
73. Hernandez-Alcoceba R., Sangro B., and Prieto J. Gene therapy of liver cancer. World J Gastroenterol 12 38 (2006) 6085-6097